Profile

New User

New to Graphy Publications? Create an account to get started today.

Registered Users

Have an account? Sign in now.

How to Cite | Author Information | Publication History | Funding Information
International Journal of Nursing & Clinical Practices Volume 9 (2022), Article ID 9:IJNCP-361, 3 Pages
https://doi.org/10.15344/2394-4978/2022/361
Short Communication
Protective Measures to Minimize Cyclophosphamide-Induced Surface Contamination Risk in Breast Cancer Patients

Noboru Hasegawa*, Tomoe Makino, Keiko Nakajima, Chisato Matsumoto, Riho Takizawa, Yuko Imakata

Ishikawa Prefectural Nursing University, 1-1 Gakuendai, Kahoku, Ishikawa 929-1210, Japan
Prof. Noboru Hasegawa, Graduate School of Nursing, Doshisha Women's College, Kodo, Kyotanabe, Kyoto 610-0395, Japan; E-mail: nhasegaw@dwc.doshisha.ac.jp
20 June 2022; 02 July 2022; 04 July 2022
Hasegawa N, Makino T, Nakajima K, Matsumoto C, Takizawa R, et al. (2022) Protective Measures to Minimize Cyclophosphamide-Induced Surface Contamination Risk in Breast Cancer Patients. Int J Nurs Clin Pract 9: 361. doi: https://doi.org/10.15344/2394-4978/2022/361
This work was supported by JSPS KAKENHI Grant Number JP16K12069.
© 2022 Hasegawa et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

References

  1. Cheng KKF, Lim YTE, Koh ZM, Tam WWS (2017) Home-based multidimensional survivorship programs for breast cancer survivors. Cochrane Database Syst Rev 8:1-116. View
  2. Kromhout H, Hoek F, Uitterhoeve R, Huijbers R, Overmars RF, et al. (2000) Postulating a dermal pathway for exposure to antineoplastic drugs among hospital workers. Applying a conceptual model to the results of three workplace surveys. Ann Occup Hyg 44: 551-560. View
  3. Meijster T, Fransman R, Veldhof R, Kromhout H (2006) Exposure to antineoplastic drugs outside the hospital environment. Ann Occup Hyg 50: 657-664. View
  4. Valero-Garcia S, Poveda-Andes JL (2018) Hazardous drugs levels in compounding area surfaces of Hospital Pharmacies Services: multicentric study. Farm Hosp 42: 152-158. View
  5. Kelsey JL (1993) Breast cancer epidemiology: summary and future directions. Epidemiol Rev 15:256–263. View
  6. Connor TH, McDiarmid MA (2006) Preventing occupational exposures to antineoplastic drugs in health care settings. CA Cancer J Clin 56: 354–65. View
  7. Makino T, Hasegawa N, Takizawa R, Matsumoto C, Wagatsuma T, et al. (2020) Suggestions for protecting breast cancer patients receiving outpatient chemotherapy and their families against the exposure risk from salivary Cyclophosphamide. Int J Nurs Clin Pract 7:320-323. View
  8. Juma FD, Rogers HJ, Trounce JR. (1979) The kinetics of salivary elimination of cyclophosphamide in man. Br J Clin Pharmacol 8: 455-458. View
  9. Kanda K, Hirai K, Iino K, Nomura H, Yasui H, et al. (2017) Salient features and outline of the Joint Japanese Guidelines for Safe Handling of Cancer Chemotherapy Drugs. Asia Pac J Oncol 4: 304-312. View
  10. Yuki M, Sekine S, Takase K, Ishida T, Sessink, PJM (2013) Exposure of family members to antineoplastic drugs via excreta of treated cancer patients. J Oncol Pharm Pract 19: 208-217. View
Best viewed in Mozilla Firefox, Google Chrome, Safari, Above IE 9.0 version
Privacy Policy | Copyright & Permissions
Copyright © 2013-2026 Graphy Publications, All Rights Reserved.